Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 355 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06131398Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, open-label trial of FPA157 in solid tumor (2 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity at 21 days, Treatment-emergent Adverse Event at 2 years and 1 more. Started Mar 2024; status: completed.
02
Drugs
FPA157
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06131398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131398.